Group 1 - The core viewpoint of the news is that Fuyuan Pharmaceutical's stock has increased by 5.01%, reaching a price of 25.76 yuan per share, with a trading volume of 432 million yuan and a turnover rate of 3.65%, resulting in a total market capitalization of 12.365 billion yuan [1] - Fuyuan Pharmaceutical, established on February 3, 1999, is located in Tongzhou District, Beijing, and was listed on June 30, 2022. The company's main business involves the research, production, and sales of pharmaceutical preparations and medical devices, with pharmaceutical preparations accounting for 94.09% of revenue and medical devices 6.00% [1] Group 2 - Among the top ten circulating shareholders of Fuyuan Pharmaceutical, a fund under E Fund ranks as a significant shareholder. The E Fund Healthcare Industry Mixed A (110023) entered the top ten circulating shareholders in the third quarter, holding 2.5638 million shares, which represents 0.53% of the circulating shares. The estimated floating profit today is approximately 3.1535 million yuan [2] - The E Fund Healthcare Industry Mixed A (110023) was established on January 28, 2011, with a latest scale of 3.802 billion yuan. Year-to-date returns are 39.49%, ranking 1421 out of 8130 in its category; the one-year return is 35.06%, ranking 1969 out of 8054; and since inception, the return is 324.9% [2] - The fund manager of E Fund Healthcare Industry Mixed A is Yang Zhenshao, who has been in the position for 9 years and 102 days. The total asset scale under management is 9.816 billion yuan, with the best fund return during the tenure being 215.53% and the worst being -12.11% [2]

Group 1 - The core point of the news is that Aosaikang's stock price dropped by 5.18% to 18.67 CNY per share, with a trading volume of 210 million CNY and a turnover rate of 1.19%, resulting in a total market capitalization of 17.329 billion CNY [1] - Aosaikang Pharmaceutical Co., Ltd. is located in Jiangning Science Park, Nanjing, Jiangsu Province, and was established on December 24, 1996. The company was listed on May 15, 2015, and its main business involves the research, production, and sales of digestive, anti-tumor, and other pharmaceuticals [1] - The revenue composition of Aosaikang's main business includes: anti-tumor drugs 38.28%, anti-infection drugs 24.74%, chronic disease drugs 21.65%, digestive drugs 12.33%, and others 3.00% [1] Group 2 - Among Aosaikang's top ten circulating shareholders, a fund under E Fund ranks as a significant shareholder. The E Fund Healthcare Industry Mixed A (110023) increased its holdings by 262,000 shares in the third quarter, holding a total of 5.7132 million shares, which accounts for 0.62% of the circulating shares [2] - The E Fund Healthcare Industry Mixed A (110023) was established on January 28, 2011, with a latest scale of 3.802 billion CNY. Year-to-date returns are 40.28%, ranking 1705 out of 8213 in its category; the one-year return is 31.56%, ranking 2111 out of 8130; and since inception, the return is 327.3% [2]

数据显示，易方达基金旗下1只基金位居迈威生物十大流通股东。易方达医疗保健行业混合A （110023）三季度新进十大流通股东，持有股数317.46万股，占流通股的比例为1.55%。根据测算，今 日浮盈赚取约704.76万元。 易方达医疗保健行业混合A（110023）成立日期2011年1月28日，最新规模38.02亿。今年以来收益 35.72%，同类排名2184/8145；近一年收益22.42%，同类排名3130/8059；成立以来收益313.4%。 易方达医疗保健行业混合A（110023）基金经理为杨桢霄。 11月13日，迈威生物涨5.07%，截至发稿，报45.98元/股，成交1.28亿元，换手率1.40%，总市值183.74 亿元。 截至发稿，杨桢霄累计任职时间9年88天，现任基金资产总规模98.16亿元，任职期间最佳基金回报 209.21%， 任职期间最差基金回报-15.64%。 资料显示，迈威(上海)生物科技股份有限公司位于中国(上海)自由贸易试验区蔡伦路230号2幢105室香港 铜锣湾希慎道33号利园1期19楼1928室，成立日期2017年5月12日，上市日期2022年1月18日，公司主营 业务涉及治疗 ...

Group 1 - The core point of the article highlights the recent performance of Fuyuan Pharmaceutical, which saw a 5.36% increase in stock price, reaching 22.98 yuan per share, with a trading volume of 100 million yuan and a turnover rate of 0.93%, resulting in a total market capitalization of 11.03 billion yuan [1] - Fuyuan Pharmaceutical, established on February 3, 1999, and listed on June 30, 2022, is primarily engaged in the research, production, and sales of pharmaceutical preparations and medical devices, with 94.09% of its revenue coming from pharmaceutical preparations and 6.00% from medical devices [1] Group 2 - Among the top ten circulating shareholders of Fuyuan Pharmaceutical, E Fund's healthcare mixed fund A (110023) entered the list in the third quarter, holding 2.5638 million shares, which accounts for 0.53% of the circulating shares, with an estimated floating profit of approximately 2.9996 million yuan [2] - E Fund's healthcare mixed fund A (110023), established on January 28, 2011, has a latest scale of 3.802 billion yuan, with a year-to-date return of 31.25%, ranking 3013 out of 8154 in its category, and a one-year return of 22.68%, ranking 3972 out of 8046 [2] - The fund manager, Yang Zhenshao, has been in the position for 9 years and 75 days, managing a total fund asset size of 9.816 billion yuan, with the best fund return during his tenure being 209.89% and the worst being -14.74% [2]

Core Viewpoint - Yuyuan Pharmaceutical experienced a 5.08% increase in stock price, reaching 25.88 CNY per share, with a total market capitalization of 11.646 billion CNY as of September 18 [1] Group 1: Company Overview - Yuyuan Pharmaceutical Group Co., Ltd. was established on August 14, 2001, and went public on December 24, 2020 [1] - The company focuses on the research and production of high-end chemical drugs, with significant revenue contributions from cardiovascular, digestive, diabetes, and anti-infection medications [1] - Major products include Ginkgo biloba extract injection, Tianma injection, Lansoprazole injection, Omeprazole enteric-coated capsules, Metformin sustained-release tablets, Cefuroxime sodium injection, and Ceftriaxone sodium injection, which are expected to drive future growth [1] Group 2: Revenue Composition - The revenue composition of Yuyuan Pharmaceutical is as follows: - Cardiovascular drugs: 55.67% - Anti-infection drugs: 20.88% - Raw materials: 8.73% - Digestive system drugs: 6.87% - Diabetes drugs: 4.85% - Others: 2.62% - Supplementary: 0.36% - Technical services: 0.02% [1] Group 3: Shareholder Information - Yuyuan Pharmaceutical's top circulating shareholder includes a fund from E Fund Management, specifically the E Fund Healthcare Industry Mixed A (110023), which entered the top shareholders list in Q2 with 6.8551 million shares, representing 1.52% of circulating shares [2] - The fund has achieved a year-to-date return of 48.1% and a one-year return of 57.01% [2]

Group 1 - The core viewpoint of the article highlights the performance of the E Fund Healthcare Industry Mixed A Fund, which has shown significant returns over various time frames [1] - As of August 24, 2025, the latest net value of the fund is 4.7380 yuan, with a weekly return of -0.94%, a three-month return of 31.94%, and a year-to-date return of 55.55% [1] - The fund was established on January 28, 2011, and as of June 30, 2025, it has a total scale of 3.944 billion yuan [1] Group 2 - The top ten stock holdings of the fund include companies such as Heng Rui Medicine, Rejig Bio, Xin Li Tai, BeiGene-U, Hai Si Ke, and others, with a total holding percentage of 58.14% [1] - The fund manager is Yang Zhenshao, who oversees the investment strategy and portfolio management [1]

Core Insights - The core viewpoint of the news is the performance and holdings of the E Fund Healthcare Industry Mixed A Fund, highlighting its recent returns and key stock positions [1]. Fund Performance - The latest net value of E Fund Healthcare Industry Mixed A is 4.7830 yuan [1]. - The fund has achieved a weekly return of 3.57% [1]. - Over the past three months, the fund's return is 44.07% [1]. - Year-to-date, the fund has generated a return of 57.03% [1]. Fund Details - E Fund Healthcare Industry Mixed A was established on January 28, 2011 [1]. - As of June 30, 2025, the fund's total assets amount to 3.944 billion yuan [1]. - The fund is managed by Yang Zhenshao [1]. Top Holdings - The top ten stock holdings of the fund include: - Heng Rui Medicine - Hotgen Biotech - Xinlitai - BeiGene-U - Haizhi Science - Nocren Health-U - Yipinhong - Kelun Pharmaceutical - Shutaishen - Baili Tianheng [1]. - The combined proportion of the top ten holdings is 58.14% [1].

Core Viewpoint - E Fund Healthcare Industry Mixed A Fund (110023) has shown significant performance with a recent net value of 4.5530 CNY, despite a slight decline of 1.73% [1] Performance Summary - The fund's one-month return is 12.81%, ranking 628 out of 4566 in its category [1] - Over the past six months, the fund has achieved a return of 48.74%, ranking 108 out of 4413 [1] - Year-to-date, the fund's return stands at 49.47%, with a ranking of 158 out of 4375 [1] Holdings Summary - The top ten stock holdings of E Fund Healthcare Industry Mixed A account for a total of 58.14%, with the following key positions: - Heng Rui Medicine: 7.39% - Rejing Biology: 7.00% - Xinlitai: 6.73% - BeiGene-U: 6.47% - Haizhi Science: 6.00% - Nocren Health-U: 5.21% - Yipinhong: 5.08% - Kelun Pharmaceutical: 5.07% - Shutaishen: 5.05% - Baili Tianheng: 4.14% [1] Fund Details - E Fund Healthcare Industry Mixed A was established on January 28, 2011, and as of June 30, 2025, it has a total scale of 3.944 billion CNY [1] - The fund manager is Yang Zhenshao, who holds a PhD in Science and has experience as an investment manager, industry researcher, and assistant fund manager at E Fund [1]

Core Viewpoint - The E Fund Healthcare Industry Mixed A Fund has shown significant performance with a year-to-date return of 51.61% as of June 30, 2025, despite a recent weekly decline of 1.56% [1]. Fund Performance - The latest net value of the E Fund Healthcare Industry Mixed A is 4.6180 yuan [1]. - The fund has achieved a return of 38.35% over the past three months [1]. - The fund was established on January 28, 2011, and has a total scale of 3.944 billion yuan as of June 30, 2025 [1]. Holdings - The top ten stock holdings of the fund include: - 恒瑞医药 (Hengrui Medicine) - 热景生物 (Hotgen Biotech) - 信立泰 (Sihuan Pharmaceutical) - 百济神州-U (BeiGene) - 海思科 (Hisun Pharmaceutical) - 诺诚健华-U (Innovent Biologics) - 一品红 (Yipinhong) - 科伦药业 (Kelun Pharmaceutical) - 舒泰神 (Shutai Shen) - 百利天恒 (Baili Tianheng) - The combined proportion of the top ten holdings is 58.14% [1].

Core Viewpoint - E Fund Healthcare Industry Mixed A Fund (110023) has shown a recent decline in net value but has performed well over various time frames, indicating strong potential in the healthcare sector [1] Fund Performance - The latest net value of E Fund Healthcare Industry Mixed A is 4.6060 CNY, down by 2.62% [1] - The fund's one-month return is 16.23%, ranking 303 out of 4679 in its category [1] - Over the past six months, the fund has achieved a return of 52.37%, ranking 91 out of 4531 [1] - Year-to-date, the fund has returned 51.21%, ranking 135 out of 4490 [1] Holdings Overview - The top ten stock holdings of E Fund Healthcare Industry Mixed A account for a total of 58.14% of the portfolio [1] - Major holdings include: - Heng Rui Medicine (7.39%) - Rejoice Bio (7.00%) - Xin Li Tai (6.73%) - BeiGene-U (6.47%) - Hai Si Ke (6.00%) - Nuo Cheng Jian Hua-U (5.21%) - Yi Pin Hong (5.08%) - Ke Lun Pharmaceutical (5.07%) - Shu Tai Shen (5.05%) - Bai Li Tian Heng (4.14%) [1] Fund Background - E Fund Healthcare Industry Mixed A was established on January 28, 2011, and as of June 30, 2025, it has a total scale of 3.944 billion CNY [1] - The fund manager is Yang Zhenshao, who holds a PhD in Science and has experience as an investment manager, industry researcher, and assistant fund manager at E Fund [1]